The Janus-like Association between Proton Pump Inhibitors and Dementia
Anna Papazoglou Muhammad I. Arshaad Christina Henseler Johanna Daubner Karl Broich Britta Haenisch Marco Weiergräber
Early pharmacoepidemiological studies suggested that Proton Pump Inhibitors (PPIs) might increase the risk of Alzheimer’s Disease (AD) and non-AD related dementias. These findings were supported by preclinical studies, specifically stressing the ...
https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico
PubMed Central (PMC)
Curr Alzheimer Res. 2021 Sep 29; 18(6): 453–469.

PMCID: PMC8778640

PMID: 34587884

The Janus-like Association between Proton Pump Inhibitors and Dementia

,1 ,1 ,1 ,1 ,2 ,2,3,4 and 1,*

Anna Papazoglou

1

Find articles by Anna Papazoglou

Muhammad I. Arshaad

1

Find articles by Muhammad I. Arshaad

Christina Henseler

1

Find articles by Christina Henseler

Johanna Daubner

1

Find articles by Johanna Daubner

Karl Broich

2

Find articles by Karl Broich

Britta Haenisch

2

3

4

Find articles by Britta Haenisch

Marco Weiergräber

1

Find articles by Marco Weiergräber

1 Experimental Neuropsychopharmacology, Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM), Kurt-Georg-Kiesinger-Allee 3, 53175 Bonn, Germany; 2Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) 53127, Kurt-Georg-Kiesinger-Allee 3, 53175 Bonn, Germany; 3German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; 4Center for Translational Medicine, Medical Faculty, University of Bonn, Bonn, Germany

* Address correspondence to this author at the Experimental Neuropsychopharmacology, Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM), Kurt-Georg-Kiesinger-Allee 3, 53175 Bonn, Germany; Tel: +49 228 99307 4358; Fax: +49 228 99307 3896; E-mail: ed.mrafb@rebeargreieW.ocraM

Copyright © 2021 Bentham Science Publishers

This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

Abstract

Early pharmacoepidemiological studies suggested that Proton Pump Inhibitors (PPIs) might increase the risk of Alzheimer’s Disease (AD) and non-AD related dementias. These findings were supported by preclinical studies, specifically stressing the proamyloidogenic and indirect anticholinergic effects of PPIs. However, further large-scale pharmacoepidemiological studies showed inconsistent results on the association between PPIs and dementia. Pharmacodynamically, these findings might be related to the LXR/RXR-mediated amyloid clearance effect and anti-inflammatory action of PPIs. Further aspects that influence PPI effects on AD are related to patient-specific pharmacokinetic and pharmacogenomic characteristics. In conclusion, a personalized (individualized) medicinal approach is necessary to model and predict the potential harmful or beneficial effects of PPIs in AD and non-AD-related dementias in the future.

Keywords: Alzheimer’s disease, dementia, LXR, pharmacodynamics, pharmacoepidemiology, pharmacogenomics, pharmacokinetics, PPARγ, proton pump inhibitor, RXR

1. INTRODUCTION

1.1. Proton Pump Inhibitors - Indications, Pharmacoepidemiology, Pharmacodynamics and Adverse Reactions

Proton Pump Inhibitors (PPIs) are widely used for the prevention and treatment of acid-related conditions such as dyspepsia, esophageal, duodenal and stomach peptic ulcers, including after endoscopic treatment for bleeding, NSAID-associated ulcers, gastroesophageal reflux disease (GERD) including endoscopy-negative reflux disease, laryngopharyngeal reflux causing laryngitis and chronic cough, Barrett’s esophagus, eosinophilic esophagitis, gastrinomas and related complex conditions, e.g. Zollinger-Ellison syndrome [1-7].

PPIs are among the top 10 prescribed medications in the world [8], and the class of PPI medications is on the World Health Organization's (WHO) List of Essential Medicines [9]. Omeprazole was the first PPI in clinical use, followed by, i.a., lansoprazole, pantoprazole, rabeprazole, esomeprazole and dexlansoprazole [10-12]. Based on the National Health and Nutrition Examination Survey (1999 to 2012), the prescription rate of PPIs nearly doubled from 4.9% to 8.3% in adults aged 40-60 years in the USA [13, 14]. Importantly, 50-70% of the patients did not meet the proper indication for PPI use, particularly hospitalized elderly individuals [15-17]. Another survey in the USA (2002-2017 Medical Expenditure Panel Survey) revealed that the overall percentage of PPI users increased from 5.70% in 2002-2003 to 6.73% in 2016-2017, also, in most patient subgroups [18]. In Germany, PPI prescriptions are also increasing. While the annual national report on drug prescription of 2018 and 2019 reveals a decrease in omeprazole prescription (quantified as Defined Daily Dose (DDD)) by 5.1%, other PPIs exhibit strong increases in prescription, e.g., pantoprazole (1.2%), lansoprazole (20.0%), esomeprazole (5.1%) and rabeprazole (1.6%) [19].

Structurally, PPIs belong to the benzimidazole family, and the activated forms covalently and irreversibly inhibit the H+/K+-ATPase by interaction with cysteine residues on the luminal surface of the parietal cells, therefore suppressing gastric acid secretion [2, 10]. The primary active H+/K+-ATPase belongs to the PII subfamily of P-type ATPases such as the Ca2+-ATPase or the Na+/K+-ATPase [20]. In humans, one of the genes encoding the H+/K+-ATPase (ATP12A/ATP1AL1) is also expressed in the brain, whereas the gene ATP4A is expressed specifically in gastric epithelial cells [21]. There is clear evidence that H+/K+-ATPase activity is present in the Central Nervous System (CNS) [22] and that the related antiporter affects acid/base and K+ homeostasis [21]. Vesicular proton pumps (H+-ATPases or V-type ATPases) are of central relevance in neurotransmitters storage in synaptic vesicles. Besides these H+-ATPases, vesicular H+/K+-ATPases also seem to play an essential role in exo- and endocytosis in nerve endings [23, 24].

A central pharmacokinetic aspect regarding PPIs is their ability to penetrate the blood-brain barrier (BBB). For instance, 15% of a single i.v. administered dose of omeprazole was reported to enter the CNS [25]. Similarly, lansoprazole was also described to penetrate the BBB [26]. Overall, PPIs such as lansoprazole, esomeprazole and pantoprazole, seem to penetrate the BBB which is in line with the occurrence of adverse neurological effects, e.g., headache, dizziness/vertigo, depression, diplopia, sleep alterations, drowsiness, insomnia, tremor, nervousness, hallucinations and delirium [27-32]. Apart from these direct adverse reactions, further neurological side effects of PPIs can originate from indirect systemic alterations, e.g., via magnesium or vitamin B12 deficiency.

Originally, PPIs were judged to have an excellent safety profile and became one of the most prescribed drugs in recent years [13, 18, 19]. With globally increasing prescription rates, the number of previously underrecognized/underestimated, potentially detrimental effects significantly increased. The latter included - dose-dependently -, stroke, myocardial infarction, nausea, vomiting, abdominal pain and constipation, increased risk of infections with clostridium difficile, non-typhoid salmonella, Campylobacter spp., Clostridium difficile and spontaneous bacterial peritonitis, vitamin B12 deficiency, iron and calcium deficiency, hypomagnesemia, musculoskeletal impairment (hip fracture, osteoporosis/osteoporotic fracture and myopathy/rhabdomyolysis), increased risk of cirrhosis-related complications such as hepatic encephalopathy, and hepatocellular carcinoma, kidney diseases (acute interstitial nephritis, acute kidney injury and chronic kidney disease), anemia, thrombocytopenia and increased risk for pneumonia [33-38]. Recently, it has also been suggested that PPI users might be more vulnerable to high COVID-19 viral loads, although the interdependence between PPI intake and COVID-19 infection/SARS-Cov2 is still under investigation [39-41]. Based on these observations, the safety profile of PPIs, particularly related to cognitive functions and dementia, has received increasing attention.

2. ALZHEIMER’S DISEASE AND NON-ALZHEI- MER’S DISEASE RELATED DEMENTIAS - EPIDEMIOLOGY AND RISK FACTORS

Based on the epidemiological World Alzheimer Report, the prevalence of dementia worldwide was rated over 46.8 million people in 2015, with an anticipated prevalence of 74.7 million by 2030 and 131.5 million by 2050. About 63% and 68% of patients suffering from dementia will be located in low- and middle-income countries by 2030 and 2050, respectively [42]. Clearly, this development will impose tremendous challenges on health care systems and therefore, dementia was designated a public health priority due to the WHO [43]. Although AD accounts for 50-70% of all cases of dementia, other non-AD related dementias also need to be considered [44]. In general, the prevalence of AD increase with age from 3.5% in patients with 75 years of age up to 46.3% in patients >95 years [45]. For the USA, the Alzheimer’s Association Report “2021 Alzheimer's Disease Facts and Figures” provides a detailed statistical resource for AD data and future perspectives. As in other countries, the prevalence and incidence of AD and non-AD related dementias are increasing and likely to escalate in the upcoming decades due to the ageing society. In the USA, prevalence of AD exhibit the following increase with age: 5.3% of people aged 65-74 years, 13.8% of people aged 75-84 years, and 34.6% of people aged >85 years suffer from AD [46]. Notably, the number of individuals >65 years is expected to increase from 58 million in 2021 to 88 million by 2050 [47]. Recent calculations suggest that in the USA, approximately 6.2 million inhabitants aged >65 years suffer from AD in 2021 [47]. Similar results were observed for incidence parameters. According to evaluations in the USA in 2011, the annual incidence in people aged 65-74 years was 0.4%; in people aged 75-84 years, the incidence turned out to be 3.2% and for individuals aged >85 years an incidence of 7.6% was detected [48, 49]. Overall, it is estimated that the incidence of AD and non-AD related dementias is about to double by 2050 [50]. Thus, one predominant risk factor for late-onset AD is older age, i.e., the incidence of AD strongly increases with age [51, 52]. Data from the Framingham Heart Study were used to calculate lifetime risks of AD dementia by age and sex [53]. The estimated lifetime risk for AD at age 45 was approximately 20% for women and 10% for men. The risks for both sexes were slightly higher at an age of 65 years [53]. Importantly, gender specific differences in prevalence, incidence and lifetime risk were consistently detected for AD and non-AD related dementias with increased parameters in females compared to males [46]. Furthermore, racial and ethnic differences in the prevalence of AD and other dementias were observed. In the USA for example, older Hispanic and Black Americans have a higher probability than older White Americans to develop AD and other dementias [48]. In general, AD is supposed to depend on multiple factors rather than a single cause. The latter holds true, e.g., for genetic alterations that can dramatically increase the risk of AD. Such genetic factors include, for example, the APOE-ε4 status [54, 55]. The APOE-ε4 gene exerts a tremendous impact on late-onset AD and is engaged in intravascular cholesterol transport. Three different alleles of the APOE gene have been characterized, i.e., ε2, ε3 and ε4, which can be arranged in six potential allelic settings: ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4 and ε4/ε4. Both racial and ethnic background affect the APOE allelic distribution [56-58]. The APOE-ε4 form poses a higher specific risk of developing AD on its owner compared to those carrying the ε3 allele. Importantly, the APOE-ε2 form is supposed to decrease the AD risk compared to APOE-ε3 carriers. Inheritance of one ε4 copy goes together with a 3-fold higher risk of developing AD compared to a ε3/ε3 carrier. Moreover, the ε4/ε4 genotype goes together with an 8-12-fold risk of AD development [59-61]. Also, ε4 inheritance increases the level of amyloid beta (Aβ) accumulation [62] and triggers AD at an earlier age compared to ε2 or ε3 carriers [63]. In the USA, 56-65% of patients diagnosed with AD turned out to be monoallelic APOE-ε4 gene carriers, whereas 11% of AD patients carried two APOE-ε4 copies [64, 65]. Importantly, long-lasting strong mental activity and challenges, complex social networking and interactions can beneficially counteract the development of AD in APOE-ε4 risk patients [66].

Genetic mutations, in general, account for a rather small percentage (< 1%) of AD cases [67]. Some are relevant in early-onset familial Alzheimer Disease (AD) and include mutations in the amyloid precursor protein (APP), presenilin 1 and presenilin 2 [68]. Complex genetic syndromes such as trisomy 21 (Down’s syndrome) represent rather uncommon genetic conditions that, however, greatly influence Alzheimer's risk [69]. Large population-based studies revealed that - although a family history of AD is not a prerequisite for developing AD - individuals with first-degree relatives with AD are more likely to develop AD than those without a first-degree relative with AD [59, 70, 71].

Numerous other risk/susceptibility factors were identified to contribute to the etiopathogenesis and clinical progression of AD (see AD continuum, i.e., preclinical AD, Mild Cognitive Impairment (MCI), mild, moderate and severe AD) and multiple more are likely to be discovered in the future [72]. Besides intrafamilial factors including heredity (genetic factors), other non-genetic, modifiable factors are also of special relevance. Modifiable risk factors associated with an increased risk of dementia include cardiovascular diseases [73], smoking [74-78], diabetes [79-82], midlife obesity [83-87], prehypertension [87], hypertension [83, 87-91], high cholesterol [92, 93], diet/nutrition, inadequate sleep or poor sleep quality [94], excessive alcohol use [95], depression [96] and hearing impairment [97]. Notably, the functional interdependence between risk factors and AD is complex, e.g., late-onset of obesity and hypertension actually seems to reduce the risk of dementia [98, 99]. It should be noted that Traumatic Brain Injury (TBI), even mild TBI, and chronic traumatic encephalopathy (e.g. in contact sports) also increase the risk of dementia [100, 101].

Further important risks factors are related to the exposure to environmental factors, e.g. substances toxic to the nervous system such as air pollution, lead and pesticides [102-104]. There is emerging evidence that exposure to air pollution, e.g., fine particulate matter air pollution, which consists of tiny solid particles and liquid droplets generated by fuel combustion, fires, and processes that produce dust, may increase the risk of dementia [105-107].

Another important risk factor is education. Individuals with formal education, a mentally stimulating environment with complex social and cultural interactions, physical activity and high socioeconomic status have a lower risk for AD and non-AD related dementias [57, 108-113]. In contrast, less years of education are accompanied by more cardiovascular risk factors, less physical activity, higher risk of diabetes [114-116], hypertension [117] and smoking [118], all of which increasing the risk of developing dementia.

It has been suggested that positive interference with modifiable risk factors is capable of preventing up to 40% of dementia cases [47]. It is important to point out that risk factors can differentially affect various types of dementia.

In summary, genetic, environmental and modifiable, non-genetic factors characterize the individual health settings, including comorbidity, multimorbidity, (poly)medication and health care factors. All these parameters contribute to the individual risk of developing AD or non-AD related dementias. The importance of a positive modification of these risk factors is also underlined by the lack of effective therapy options in AD and related dementias.

3. PPI MEDICATION AND DEMENTIA - CLINICAL TRIALS AND PHARMACO EPIDEMIOLOGICAL STUDIES

In the beginning of this century, some studies first raised concerns of a potential impairment of cognitive function and increased risk of conversion to MCI, dementia in general, and specifically AD among PPI users. Subsequently, these findings triggered a number of further studies and investigations (Table 1).

In 2015, Haenisch et al. reported results from a longitudinal, multicenter cohort study in elderly primary care patients (German Study on Aging, Cognition and Dementia in Primary Care Patients, AgeCoDe). Patients receiving PPI medication had a significantly increased risk of any dementia and AD in specific compared with non-users [119]. Later, the same group presented additional results from a prospective cohort study using observational data from 2004 to 2011, derived from the largest German statutory health insurer in elderly patients. Those receiving regular PPI medication were reported to have a significantly increased risk of incident dementia compared with patients not receiving PPI medication [14]. Both studies considered covariates as potential confounding factors, i.e., age, sex, comorbidities/multimorbidity and polypharmacy. In addition, Haenisch et al. (2015) took into account the APOE-ε4 allele carrier status and the educational level.

Many authors raised concerns regarding interference with further confounders, such as alcohol use/abuse, hypertension, but also prion infection susceptibility [120-129]. Nguyen and Hur (2016) specifically questioned the proposed underlying mechanism of action linking dementia and PPI use. The latter suggested that the modulation of enzymatic activity may result in increased Aβ levels. Thus, open questions also remained concerning the potential mechanism(s) related to other forms of dementia [127]. Keller (2016) specifically raised the confounding factor of dietary aluminium ingestion which is speculated to play a pathophysiological role in the onset and progression of dementia [128, 130]. Meta-analysis revealed that individuals exposed to aluminum were 71% more likely to develop AD [131]. It is also likely that patients with indication for PPI use have used strong antacids containing aluminum hydroxide which might have interfered with the observed association reported by Gomm et al. (2016).

Most important, both studies by Haenisch et al. (2015) and Gomm et al. (2016) initiated a number of subsequent investigations to gain further insight and clarification regarding the functional interdependence between PPIs and AD or non-AD related dementias (Table 1).

A literature search by Wijarnpreecha et al. (2016) including four observational studies and another small interventional study carried out by Akter et al. (2015) seemed to support the hypothesis of an increased risk of dementia among PPI users [17, 132]. Apparently, these findings were also backed up by preclinical data that suggested that PPIs can enhance Aβ (Aβ37, Aβ40 and Aβ42) production. Aβ is derived from the sequential cleavage of the Amyloid Precursor Protein (APP) by β- and γ-secretases and was found to be increased in both cellular and animal models upon PPI exposure [133]. Recently, Kumar et al. (2020) reported that PPIs also act as inhibitors of the choline acetyltransferase (ChAT) and that this mechanism might serve as an ultimate biochemical explanation for the potentially increased incidence of dementia upon PPI use [134]. Various other pathobiochemical and pathophysiological implications of PPIs related to AD and non-AD related dementias have been reported including the interaction with tau protein and effects on the neuronal microenvironment [135].

Notably, both early preclinical and clinical findings have now triggered a number of large-scale clinical trials worldwide to get further insight into the potential association between the use of PPIs and the risk of dementia. Importantly, most of these subsequent trials and meta-analyses could not confirm the initial alerting results: A case-control study including primary care patients (aged 70-90 years with 11,956 cases and 11,956 controls) with first diagnosis of dementia showed that the use of PPIs correlated with a decreased risk of developing dementia [136]. An observational, longitudinal study by Goldstein et al. (2017) revealed that PPI intake was not accompanied with a greater risk of dementia or of AD [7]. A Finnish nationwide nested case-control study also did not find a clinically meaningful association between PPI use and risk of AD [137]. The analysis of prospectively collected data of the Nurses' Health Study II did not reveal a convincing association between PPI use and cognitive function or any evidence for an increased risk of dementia [138]. A prospective population-based cohort study by Gray et al. (2018) demonstrated that PPI use did not increase the risk of dementia, even in individuals with high cumulative PPI exposure [139]. Studies by Moayyedi et al. (2017) using health care registry data could also not reveal a correlation between PPI use and AD, even with long-term or high-dosage use [140]. At that time, a meta-analysis and systematic review on information available so far on dementia, cognitive impairment and PPI treatment pointed out the inconsistent results and methodological limitations and requested for further studies [141].

Next, a case-control analysis on the UK-based Clinical Practice Research Datalink (CPRD) found no evidence of increased risk of AD-related dementias to PPIs [142]. Hwang et al. (2018) reported from a population-based longitudinal study that was based on the Korean National Health Insurance Corporation claims database merged with national health examination data for the period 2002-2013. The study revealed no increased risk of dementia upon PPI use [143]. A large-scale, multi-center, population-based study using electronic health data from the SAIL (Secure Anonymised Information Linkage) Databank in Wales (UK) revealed no association between PPI use and increased risk of dementia [144]. Another large community-based retrospective cohort including data from 2002 to 2015 in the Catalan health service (CatSalut) system revealed no higher incidence of AD among PPI users. However, a minor increase in the risk of non-AD related dementias among PPI users was detected [145]. A recent study testing neuropsychological functioning in healthy adults with familial risk factors for dementia (APOE-ε4 carrier status) could not detect any association with memory decline [146]. A population based cohort study from West Pomerania (Germany) investigated the effects of PPI treatment on brain volume, estimated brain age and cognitive function. No relationship between PPI use and brain aging was detected [147]. In addition, several meta-analyses were recently published using, i.a., PubMed, Web of Science, Embase, Google Scholar, and Cochrane library databases to examine a potential association between PPIs and AD [148-151]. None of these studies provided evidence that PPI intake increases dementia and AD risk. Zhang et al. (2020), however, performed a meta-analysis which is in support of an association between PPIs and dementia [152, 153]. Potential reasons are different inclusion/exclusion criteria for the different studies. The authors, for example, included only cohort studies, as case-control studies could introduce selection and recall biases. Furthermore, in cohort studies, the demonstration of causality was judged to be stronger. Finally, quality criteria also play an important role. The results are also affected by stratification, e.g., of age of the participants, the follow-up time, the location of the study and most importantly, the adjustment of potential confounding factors. Also, the primary outcome of interest differs, focusing on AD, non-AD related dementias, or all dementias.

A recent scoping review by Thunell et al. (2021) analyzed reports about drug classes and associated increasing or decreasing AD or related dementia risk. Besides tetracyclic antidepressants, antispasmodics and antihistaminics, a hypothesized increased risk for dementia was also attributed to PPIs [154]. The authors also confessed that there is a mixed picture of PPI effects on dementia.

The general drawbacks of retrospective studies are nicely pinpointed by reports of Tai et al. (2017), Chen et al. (2020) and Wu et al. (2020). All three studies rely on population-based retrospective cohort studies using the same Taiwan National Health Insurance Research Database (NHIRD). The data coverage and the pharmacoepidemiological analytical details differ in some points. Whereas Tai et al. (2017) and Chen et al. (2020) suggest that PPI users exhibited a significantly elevated risk of dementia compared to PPI non-users, Wu et al. (2020) clearly indicated that no association between PPI uptake and risk of developing dementia was detected [155-157].

It should be noted that there are further studies on PPIs and dementia/cognitive decline that were published in national journals only [158] or as case reports [31, 159-161]. Some studies have focused on PPI use and delirium [162, 163]. All these studies are not further discussed in this summary.

Importantly, none of the studies carried out so far met Randomized Controlled Trials (RCT) criteria that reflect the gold standard of clinical trials [154]. Thus, to evaluate and establish direct cause and effect relationships between PPI use and incident dementia in the elderly, randomized, prospective clinical trials are needed.

4. PPIs AND DEMENTIA - RELEVANCE OF PHARMACODYNAMICS, PHARMACOKINETICS AND PHARMACOGENOMICS

Obviously, early and recent pharmacoepidemiological results on PPIs and dementia are diverse which is likely to be related to the characteristics of specific study designs, different patient populations, and potential limitations of data sources, including unknown/masked confounding factors [1].

Often used data sources for pharmacoepidemiological analyses such as claims data have several advantages, e.g. analyses can be performed in a real-life setting in an unselected patient population. Health claims data cover the total population, including people who live in institutions such as nursing homes or assisted living. Furthermore, recall bias or selection bias is avoided because of the use of routine health care records. Limitations include residual confounding despite adjusting for several potential confounding factors. In particular, claims data mostly lack detailed socioeconomic, laboratory, or genetic parameters.

An additional aspect that might shed new and clarifying light on the potential controversy about PPI effects on AD and non-AD related dementias is associated with the biochemical and physiological, i.e. the pharmacodynamic effects of PPIs. Many, if not most, drugs are indeed multi-target in character and the same holds true for PPIs [164]. It is beyond the scope of this review to elaborate the etiopathogenesis of the various types of dementia described so far. To illustrate the complex functional interdependence between PPIs and dementive processes, we will therefore focus on AD and how PPIs might interfere with the related etiology and pathogenesis. As outlined above, the central histopathological hallmarks of AD comprise the deposition of extracellular Aβ plaques (Aβ dyshomeostasis, amyloid hypothesis) and intracellular neurofibrillary tangles (NFTs) originating from hyperphosphorylated tau protein. Both processes result in neurodegeneration and progressive neuronal cell loss [94, 165].

Whereas early pharmacoepidemiological studies - in favor of an association between PPIs and AD - referred to the potential increase of Aβ and alterations in vitamin B12 homeostasis upon PPI intake as potential pathophysiological mechanisms [135], it is mandatory to point out that PPIs were also reported to exert anti-amyloidogenic and anti-inflammatory biochemical effects and might thus be beneficial in AD. PPIs for example are known to exert anti-inflammatory actions. Inflammatory processes such as astrocytic activation are involved in the pathogenesis of different neurodegenerative diseases. Hashioka et al. (2011) demonstrated that PPIs attenuate interferon gamma (IFN-γ)-induced neurotoxicity of human astrocytes via suppression of the signal transducer and activator of transcription 3 (STAT3) signaling pathway. PPIs with antineurotoxic properties were thus speculated to serve as a potential treatment option in AD and other neuroinflammatory disorders associated with activated astrocytes [166-168]. A striking biochemical mechanism that seems largely underestimated, is the interference of PPIs with Liver X Receptors (LXRs) [169]. LXRα and LXRβ serve as transcription factors that control gene expression primarily related to cholesterol metabolism. Within the CNS, cholesterol metabolism is relevant for APP proteolytic cleavage, secretase activities, Aβ aggregation and clearance [169]. Importantly, LXR mediates the transcriptional control of APOE which plays a crucial role in AD [170]. Cronican et al. (2010) demonstrated that PPIs, such as lansoprazole act as LXR agonists and enhance the expression of LXR modulated target genes [171, 172]. Whereas lansoprazole increased APOE levels in primary wild-type astrocytes, this effect was abolished in LXRα/β double KO mice. Notably, other PPIs also exhibit agonistic effects on LXR with different efficiencies [171]. In 2015, these results were further supported by studies of Skerrett et al., who demonstrated that LXRs- and peroxisome-proliferator receptor γ (PPARγ)- agonists reduce Aβ levels as both soluble and deposited forms of Aβ. They further improve cognitive deficits in AD mouse models by inducing transcription and lipidation of APOE and by suppression of microglial proinflammatory genes [173]. These beneficial effects were also confirmed on the behavioral level in an AD mouse model [174].

The LXR/PPARγ pathway is likely to play an essential role in the interpretation of recent pharmacoepidemiologic results and the planning of future studies. The clearance of Aβ from the CNS is known to be dependent on the APOE gene related polymorphism being facilitated by APOE-ε2 [170]. The latter is transcriptionally regulated by PPARγ and LXR, in combination with the Retinoid X Receptor (RXR) [175]. Compelling results demonstrated that the RXR agonist bexarotene, originally approved for the treatment of cutaneous T cell lymphoma, dramatically enhances APOE mediated clearance of soluble and deposited Aβ and restores cognitive deficits in various AD mouse models [176-180]. Similar results were observed for PPARγ agonists such as pioglitazone. The latter stimulates Aβ degradation by both microglia and astrocytes via LXR and APOE activation in AD mouse models, e.g., APP/PS1. Amyloid deposits were removed, microglia and astrocytes were massively recruited for clearance, and memory deficits were restored in PPARγ agonist treated mice [181, 182].

Another PPI interdependence with AD was suggested to be based on prion infections. In mice, the acidic gastric juice was shown to protect against prion infection [183]. Prions are known to trigger/induce neurodegenerative processes. Notably, this phenomenon seems to be underestimated in general [183].

It is obvious that pathophysiologically, either a decrease of Aβ production or an increase of Aβ clearance is beneficial in AD treatment. As outlined above, the armamentarium of pharmacodynamic properties of PPIs covers various biochemical, cellular actions such as enhanced Aβ production, ChAT-inhibition, LXR-receptor and APOE activation with potentially enhanced Aβ clearance, disturbance of vitamin B12 homeostasis, attenuated IFN-γ-induced neurotoxicity and suppression of the STAT3 signaling pathway, V-ATPase inhibition of lysosomes with reduced clearance of Aβ, or other yet discovered and still unknown mechanisms [135, 164]. Pharmacodynamically, PPIs can clearly trigger opposing mechanisms, i.e., an increase in Aβ production and proinflammation on the one hand, and increased clearance of soluble Aβ and amyloid plaques from the CNS facilitated by APOE with anti-inflammatory action on the other hand. At a first glance, the Janus-like discrepancies in pharmacoepidemiologic results (Table 1) might solely originate from differences in study designs and multiple inherent known and unknown confounding factors. However, given their multi-target character, PPIs might exert a net pharmacodynamic effect in Aβ homeostasis which either aggravates or reduces Aβ production, Aβ clearance, inflammatory processes and the cognitive/behavioral phenotype. However, this net effect itself might be dependent on the various pharmacokinetic parameters of the different PPI members, such as BBB permeability or cytochrome P450 (CYP) dependent metabolization. Other patient related (risk) factors such as the individual APOE gene related polymorphism might be of central importance here as well [170, 184].

CONCLUSION

Currently, PPIs are important and practically irreplaceable drugs in the prevention and treatment of specific medical conditions for defined periods of time [185]. However, numerous adverse reactions became obvious, particularly following excessive and prolonged treatment with PPIs. Clearly, as regards the controversial implications of PPIs in AD and non-AD related dementias, further studies, particularly RCT need to be conducted. It might be hypothesized that a future solution will originate from a personalized medicinal approach, in which individualized pharmacokinetic and pharmacogenomic data of patients are modelled to predict the potential harm or benefit of short and long-term use of PPIs on AD and non-AD related dementias.

​

Table 1

Studies / Publications Study Design / Data Origin Country Study Group Sizes / Characteristics Types of Dementia / Parameters Investigated Potential Confounders Considered / Limitations Conclusions Haenisch et al. (2015) Longitudinal, multicenter cohort study in elderly primary care patients (German Study on Aging, Cognition and Dementia in Primary Care Patients, AgeCoDe).Germany3,327 community-dwelling persons aged ≥ 75 years.AD and non-AD related dementias.Age, sex, education, ApoE4 allele status, polypharmacy, comorbidities, i.a. depression, diabetes, ischemic heart disease, and stroke.Patients receiving PPI medication had a significantly increased risk of any dementia. Akter et al. (2015) Computerized neuropsychological testing using the Cambridge Neuropsychological Test Automated Battery.BangladeshSixty volunteers of either gender (age range 20-26 years).Visual memory, executive functions, working memory, planning and strategy development, speed of response, and sustained attention.Short-term PPI adminstration, limited sample size.Significant impairment in visual memory, attention, executive function, and working and planning function upon PPI uptake. Gomm et al. (2016) Prospective cohort study using observational data from 2004 to 2011, derived from the largest German statutory health insurer (Allgemeine Ortskrankenkassen, AOK).Germany73,679 participants, aged ≥ 75 years, free of dementia at baseline.AD and non-AD related dementias.Analysis was adjusted for potential confounding factors, including age, sex, comorbidities, and polypharmacy.Patients receiving regular PPI medication had a significantly increased risk of incident dementia compared with the patients not receiving PPI medication. Wijarnpreecha et al. (2016) Literature search performed in the MEDLINE and EMBASE database from inception to April 2016.See related original studies / databasesSee related original studies / databases.See related original studies / databases.See related original studies / databases.Increased risk of dementia among PPI users. Booker et al. (2016) Case-control study including German primary care patients with first diagnosis of dementia (all-cause) during the index period (01/2010-12/2014).Germany11,956 cases (initial diagnosis of dementia, all causes) and the 11,956 controls (without dementia), aged 70-90 years. Participants were matched on the basis of age, sex, type of health insurance, and physician.AD (Alzheimer's disease (G30)) and related dementias (vascular dementia (F01) and unspecified dementia (F03)).Diabetes, lipid metabolism, stroke incl. Transient Ischemic Attack (TIA), Parkinson's Disease (PD), intracranial injury, coronary heart disease, Mild Cognitive Impairment (MCI), mental and behavioral disorders due to alcohol use. Related medication was also assessed.PPIs were associated with a decreased risk of developing dementia. Goldstein et al. (2017) Observational, longitudinal study, data from National Alzheimer’s Coordinating Center (NACC) database from 33 Alzheimer's Disease Centers from September 2005 through September 2015 (NIH-NIA supported).USA10486 persons aged ≥ 50 years (all had baseline normal cognition (n = 7,404) or MCI (n = 3,082)).ADDemographic characteristics, vascular comorbidities, metabolic disorders, mood, polypharmacy, i.a., use of anticholinergics and antihistamines, reliance on self-reported PPI use and lack of dispensing data.PPIs were not associated with greater risk of dementia or of AD. Continuous or intermittent PPI use was associated with lower risk of decline in cognitive function and lower risk of conversion to MCI or AD. This lower risk was found for persons with normal cognition or MCI. Taipale et al. (2017) A Finnish nationwide nested case-control study (MEDALZ). Data were derived from a Finnish nationwide health-care register, including Special Reimbursement Register, Prescription Register, Hospital Discharge Register.FinlandCommunity- dwelling individuals with newly diagnosed AD during 2005-2011 (n = 70,718), and up to four age-, sex-, and region of residence-matched comparison individuals for each case (n = 282,858)ADCardiovascular diseases (hypertension, coronary artery disease, chronic heart failure, chronic arrhythmias), diabetes, stroke, depression, polypharmacy.PPI use was not associated with risk of AD with 3-year lag window applied between exposure and outcome. Longer duration of use was not associated with risk of AD. Higher dose use was not associated with an increased risk. In conclusion, no clinically meaningful association between PPI use and risk of AD was detected. The results for longer duration of cumulative use or use with higher doses did not indicate dose-response relationship. Lochhead et al. (2017) Prospectively collected data on medication use and other potential risk factors from the Nurses' Health Study II (NHS II, based on self-administered computerized neuropsychological test battery).USA13,864 female participants (aged 50–70 years).Assessment of cognitive function.Education level, comorbidities (smoking status, alcohol consumption, cardiovascular diseases, metabolic disorders, BMI, etc.), polypharmacy.The study results do not support the suggestion that PPI use increases dementia risk. Batchelor et al. (2017) Systematic review (meta-analysis) according to the PRISMA statement (registered on PROSPERO).See related original studies / databasesRelevant studies were identified in Medline, EMBase, Cochrane Central Register of Controlled Trials (CENTRAL), PSYCinfo, Scopus, Web of Science and ClinicalTrials.gov. Eleven studies were included (with four studies investigating PPI use and dementia and seven studies exploring PPI use and acute cognitive impairment).AD, non-AD dementias and acute cognitive impairment (see also related original studies / databases).Familiy history of dementia, hypertension, diabetes, physical exercise, air pollution, intestinal microbiota, aluminium containing medications and medication in general (see also related original studies / databases).The interpretation of the reported association between PPI treatment and dementia is hampered by methodological aspects and potential bias. The latter require future longitudinal studies. Tai et al. (2017) Population-based retrospective cohort study using the Taiwan National Health Insurance (NHI) claims database-National Health Insurance Research Database (NHIRD).TaiwanPatients initiating PPI therapy between January 2000 and December 2003 without a prior history of dementia. Analysis of data of 15726 participants aged >40 years. PPI users (n = 7,863), non- PPI users (n = 7,863).AD and non-AD dementias.Comorbidities included, i.e., diabetes mellitus, hypertension, hyperlipidemia, peripheral vascular disease, ischemic heart disease, depression, and ischemic stroke. Potential confounding drugs included anticoagulants, NSAIDs, antiplatelet agents, antidiabetic agents, antihypertensives, and statins.An increased risk for dementia was identified among the Asian PPI users. Cumulative PPI use was significantly associated with dementia. Gray et al. (2018) Prospective population-based cohort study (Kaiser Permanente Washington, an integrated healthcare delivery system in Seattle, Washington).USAIndividuals aged ≥ 65 years without dementia at study entry (n = 3,484).AD and non-AD dementias.Demographic characteristics (age at study entry, sex, years of education), medical history (cardiovascular disorders, metabolic diseases), health behaviors (BMI, smoking behavior, exercise, mood disorders), functional measures and medications.PPI use was not associated with dementia risk, even for people with high cumulative exposure. Imfeld et al. (2018) A case-control analysis on the UK-based Clinical Practice Research Datalink (CPRD) through a license from the UK Medicines and Healthcare products Regulatory Agency (MHRA).UK41,029 patients aged ≥ 65 years with newly diagnosed AD, vascular dementia or unspecified dementia between 1998 and 2015.AD, vascular dementia and unspecified dementia.Age, sex, calendar time, general practice, and number of years of recorded history were matched between groups. Comorbidities and co-medications at or within the year prior to the index date were considered. Covariates include arterial hypertension, diabetes mellitus, coronary heart disease, atrial fibrillation, stroke, depression, and polypharmacy (i.a., of platelet aggregation inhibitors, anticoagulants, NSAIDs, SSRIs, SNRIs).Long-term PPI use was not associated with an increased risk of developing AD or VaD. Hwang et al. (2018) A population-based longitudinal study using the Korean National Health Insurance Corporation claims database merged with national health examination data for 2002-2013.Republic of KoreaThe study cohort included 70,529 individuals who were free of dementia in 2007. Incident dementia was assessed throughout follow-up until 2013. 1,297 participants developed dementia during the study period.AD and non-AD dementias.Covariates included pulmonary diseases, renal diseases, liver diseases, metabolic disorders.PPI use was not associated with an increased risk of dementia. PPI use was not associated with increased risk. Li et al. (2019) Meta-analysis to determine potential association of PPI use and risk of dementia among older people.See related original studies / databasesStudies were identified in PubMed, EMBASE, and Cochrane Library databases from inception to February 2018. Cohort studies that had identified a risk of dementia or AD among PPI users compared with non- PPI users were considered. Quality of studies was catagorized via the Newcastle-Ottawa Scale (NOS). Six cohort studies were selected.See related original studies / databases.See related original studies / databases.No significant association between PPI intake and risk of dementia or AD could be detected. Song et al. (2019) Meta-analysis to investigate the risk of dementia and AD among PPI users.See related original studies / databasesRelevant studies were identified in PubMed, Web of Science, EMBase and ScienceDirect. Ten independent studies with 642,305 participants were included.See related original studies / databases.See related original studies / databases.PPI intake does not increase the risk of dementia and AD. Torres-Bondia et al. (2020) A community-based retrospective cohort study based on data available from 1st January 2002 to 31st December 2015 in the Catalan health service (CatSalut) system.Catalonia / SpainPPI users (n = 36,360) and non-users (n = 99,362) aged ≥ 45 years. A lag window of 5 years was considered between the beginning of the PPI treatment and the diagnosis of dementia.AD and non-AD dementias.Age, sex, hypertension, diabetes and dyslipidaemia were considered as confounding variables.PPI use was not associated with the risk of AD. A weakly but significantly increased risk of non-AD dementias was observed among PPI users. A higher dose of PPIs was not associated with an increased risk of either AD or non-AD dementias. An increased risk of AD and non-AD dementias was detected in users of two types of PPIs compared with one type PPI users. Cooksey et al. (2020) Large-scale, multi-centre, population-based study using electronic health-data from the Secure Anonymised Information Linkage (SAIL) Databank, Wales (UK) from 1999 to 2015.UK183,968 persons who had ever been prescribed PPIs, aged ≥ 55 year, compared to 131,110 non-PPI exposed individuals.AD and non-AD dementias.Personal characteristics (e.g., age, sex, smoking status, obesity, alcohol consumption), confounding comorbidities (diabetes, cardiovascular disease, depression, anxiety, head injury, hypertension, high cholesterol, vitamin-B12 deficiency), concomitant medications (anxiolytics, anti-depressants, anticoagulants, antiplatelets, statins, hormone replacement therapy (HRT), vitamin-B12 supplements, iron and antihypertensives).No association between PPI use and increased dementia risk was detected. Desai et al. (2020) Meta-analysis to investigate a potential association between PPI use and the risk of dementia.See related original studies / databasesLiterature search in PubMed, Embase, Google Scholar, and Cochrane for studies investigating the risk of cognitive decline and dementia among PPI users versus non-PPI users in prospective studies.See related original studies / databases.Retrospective database linkage studies, case reports, case series, editorials, uncontrolled cohort studies, cross-sectional studies, and review articles were excluded.No significant relationship between PPI use and dementia in prospective studies with at least a 5-year follow-up. Khan et al. (2020) Meta-analysis to investigate a potential association between PPI intake and the risk of dementia.See related original studies / databasesLiterature / study search in MEDLINE, EMBASE, ISI Web of Science, and Cochrane databases, up to February 2019. Quality categorisation of observational studies was assessed using the Newcastle-Ottawa scale and the GRADE approach. Eleven studies were included comprising 642,949 individuals.See related original studies / databases.See related original studies / databases.No evidence for an association between PPI use and increased risk of dementia. Zhang et al. (2020) Meta-analysis to investigate a potential association between PPI intake and the risk of dementia.See related original studies / databasesLiterature search in English and Chinese databases from origination to December 2018. Six studies were considered, including a total of 166,146 participants.See related original studies / databases.See related original studies / databases. Exclusion criteria included animal experimental models, systematic review articles, letters, meta-analyses, comments, case reports; duplicated studies, studies without possibility to retrieve or calculate data of interest.Result show a significant increase in dementia risk with PPI use. Subgroup analyses revealed a significant association between PPI use and the risk of dementia in Europe and among participants aged ≥ 65 years. Chen et al. (2020) Population-based retrospective cohort study using the Taiwan National Health Insurance (NHI) claims database-National Health Insurance Research Database (NHIRD).TaiwanPatients aged ≥ 65 years with cumulative PPI use between January 2000 and December 2005 (PPI user cohort n = 6,584; PPI non-user cohort, n = 6,584).AD and non-AD dementias.Covariates included sex, age, comorbidities (e.g. diabetes mellitus, hyperlipidemia, coronary artery disease, stroke, depression) and comedication (e.g. NSAIDs, anti-hypertensives, anti-diabetic agents, statins, aspirin, and anti-depressants).PPI users exhibited a significantly elevated risk of dementia compared to PPI non-users. Wu et al. (2020) Population-based propensity score matched retrospective cohort study using Taiwan's National Health Insurance (NHI) Research Database.TaiwanPatients aged ≥ 40 years with PPIs use between 2000 and 2010 (PPI user cohort compared to PPI non-user cohort, n = 2,583 each).AD and non-AD dementias.Covariates considered: age, sex, hypertension, diabetes mellitus, coronary artery disease, hyperlipidaemia, stroke, asthma, chronic renal failure, depression.No association between PPI uptake and a risk of developing dementia was detected. Collin et al. (2021) Wisconsin Registry for Alzheimer’s Prevention study.USAQuestionnaires on medical history, blood samples and neuropsychological assessments from n = 1,573 individuals over a 10–15 year period.AD and non-AD dementias.Covariates included gender, antihypertensive drug use, physical activity, cigarette use, APO ε4 carrier status, H2RA use, heart disease, diabetes, depression, anxiety, lung disease.PPI use was not associated with memory decline in a sample of subjects with familial risk factors for dementia. Ahn et al. (2020) Population-based cohort Study of Health in Pomerania (SHIP).GermanyParticipants aged 21 - 89 years, n = 2653 (baseline examinations 1997-2001, follow-up examination 2002-2006 and 2008-2012).Brain volume (MRI), estimated brain age and cognitive function (Verbal Learning and Memory Test, VLMT; Nuremberg Age Inventory, NAI).Multiple regression used to adjust confounding factors, e.g. age, sex, BMI, cognitive function-altering medications and further medication, socio-demographic variables, income, educational level, smoking experience, alcohol consumption, diabetes and cerebrovascular pathologies.No relationship between PPI use and brain aging was detected. Thunell et al. (2021) Meta-analysis / scoping review to identify drug classes (including PPIs) associated with increasing or decreasing risk for AD or related dementiasSee related original studies / databasesSystematic search using PubMed, SCOPUS, and Cochrane Central Register of Controlled Trials (CENTRAL) databases for all published studies on humans from January 2008 till August 2018.See related original studies / databases.See related original studies / databases.Twelve observational and four review studies examining PPIs were considered and exhibited mixed findings. Five of the 12 studies described increased risk of dementia or cognitive decline, two reported neuroprotective benefits, and five were inconclusive.

ACKNOWLEDGEMENTS

Declared none.

LIST OF ABBREVIATIONS

ADAlzheimer’s DiseaseAPPAmyloid Precursor ProteinBBBBlood Brain BarrierChATCholine AcetyltransferaseCNSCentral Nervous SystemGERDGastroesophageal Reflux DiseaseINFInterferoneLXRLiver X ReceptorMCIMild Cognitive ImpairmentPPARγPeroxisome-Proliferator Receptor γPPIProton Pump InhibitorRXRRetinoid X ReceptorSTAT3Signal Transducer And Activator of Transcription 3

Funding Statement

This work was supported by the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM, Bonn, Germany).

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

This work was supported by the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM, Bonn, Germany).

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

References

1. Savarino E., Marabotto E., Zentilin P., Furnari M., Bodini G., Pellegatta G., Lorenzon G., Della Coletta M., Ghisa M., Coppo C., Marinelli C., Savarino V. A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opin. Drug Saf. 2018;17(8):785–794. doi: 10.1080/14740338.2018.1497155. [PubMed] [CrossRef] [Google Scholar]

2. Shin J.M., Sachs G. Pharmacology of proton pump inhibitors. Curr. Gastroenterol. Rep. 2008;10(6):528–534. doi: 10.1007/s11894-008-0098-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Strand D.S., Kim D., Peura D.A. 25 Years of proton pump inhibitors: A comprehensive review. Gut Liver. 2017;11(1):27–37. doi: 10.5009/gnl15502. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Pinto-Sanchez M.I., Yuan Y., Hassan A., Bercik P., Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst. Rev. 2017;11:CD011194. [PMC free article] [PubMed] [Google Scholar]

5. Freedberg D.E., Kim L.S., Yang Y.X. The risks and benefits of long-term use of proton pump inhibitors: Expert review and best practice advice from the American gastroenterological association. Gastroenterology. 2017;152(4):706–715. doi: 10.1053/j.gastro.2017.01.031. [PubMed] [CrossRef] [Google Scholar]

6. Scarpignato C., Gatta L., Zullo A., Blandizzi C. Group S-A-F, Italian society of pharmacology tIAoHG. . Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. doi: 10.1186/s12916-016-0718-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

7. Goldstein F.C., Steenland K., Zhao L., Wharton W., Levey A.I., Hajjar I. Proton pump inhibitors and risk of mild cognitive impairment and dementia. J. Am. Geriatr. Soc. 2017;65(9):1969–1974. doi: 10.1111/jgs.14956. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Juntunen H., Taipale H., Tanskanen A., Tolppanen A.M., Tiihonen J., Hartikainen S., Tiihonen M. Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer’s disease. Eur. J. Clin. Pharmacol. 2017;73(9):1149–1158. doi: 10.1007/s00228-017-2273-8. [PubMed] [CrossRef] [Google Scholar]

9. WHO. World Health Organization model list of essential medicines: 21st list 2019. World Health Organization. 2019. Available from: https://appswhoint/iris/handle/10665/325771.

10. Shin J.M., Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J. Neurogastroenterol. Motil. 2013;19(1):25–35. doi: 10.5056/jnm.2013.19.1.25. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

11. Sachs G., Shin J.M., Howden C.W. Review article: the clinical pharmacology of proton pump inhibitors. Aliment. Pharmacol. Ther. 2006;23(Suppl. 2):2–8. doi: 10.1111/j.1365-2036.2006.02943.x. [PubMed] [CrossRef] [Google Scholar]

12. Helgadottir H., Bjornsson E.S. Problems associated with deprescribing of proton pump inhibitors. Int. J. Mol. Sci. 2019;20(21):E5469. doi: 10.3390/ijms20215469. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Kantor E.D., Rehm C.D., Haas J.S., Chan A.T., Giovannucci E.L. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015;314(17):1818–1831. doi: 10.1001/jama.2015.13766. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Gomm W., von Holt K., Thomé F., Broich K., Maier W., Fink A., Doblhammer G., Haenisch B. Association of proton pump inhibitors with risk of dementia: A pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410–416. doi: 10.1001/jamaneurol.2015.4791. [PubMed] [CrossRef] [Google Scholar]

15. Heidelbaugh J.J., Inadomi J.M. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am. J. Gastroenterol. 2006;101(10):2200–2205. doi: 10.1111/j.1572-0241.2006.00839.x. [PubMed] [CrossRef] [Google Scholar]

16. Eid S.M., Boueiz A., Paranji S., Mativo C., Landis R., Abougergi M.S. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern. Med. 2010;49(23):2561–2568. doi: 10.2169/internalmedicine.49.4064. [PubMed] [CrossRef] [Google Scholar]

17. Akter S., Hassan M.R., Shahriar M., Akter N., Abbas M.G., Bhuiyan M.A. Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software. Alzheimers Res. Ther. 2015;7:79. doi: 10.1186/s13195-015-0164-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Mishuk A.U., Chen L., Gaillard P., Westrick S., Hansen R.A., Qian J. National trends in prescription proton pump inhibitor use and expenditure in the United States in 2002-2017. J. Am. Pharm. Assoc. (Wash. D.C.) 2021;61(1):7. doi: 10.1016/j.japh.2020.09.015. [PubMed] [CrossRef] [Google Scholar]

19. Schwabe U., Ludwig W-D. Arzneiverordnungs-Report 2020. Springer; 2020. [CrossRef] [Google Scholar]

20. Bublitz M., Poulsen H., Morth J.P., Nissen P. In and out of the cation pumps: P-type ATPase structure revisited. Curr. Opin. Struct. Biol. 2010;20(4):431–439. doi: 10.1016/j.sbi.2010.06.007. [PubMed] [CrossRef] [Google Scholar]

21. van Driel I.R., Callaghan J.M. Proton and potassium transport by H+/K(+)-ATPases. Clin. Exp. Pharmacol. Physiol. 1995;22(12):952–960. doi: 10.1111/j.1440-1681.1995.tb02332.x. [PubMed] [CrossRef] [Google Scholar]

22. Modyanov N.N., Petrukhin K.E., Sverdlov V.E., Grishin A.V., Orlova M.Y., Kostina M.B., Makarevich O.I., Broude N.E., Monastyrskaya G.S., Sverdlov E.D. The family of human Na,K-ATPase genes. ATP1AL1 gene is transcriptionally competent and probably encodes the related ion transport ATPase. FEBS Lett. 1991;278(1):91–94. doi: 10.1016/0014-5793(91)80091-G. [PubMed] [CrossRef] [Google Scholar]

23. Wang D., Hiesinger P.R. The vesicular ATPase: a missing link between acidification and exocytosis. J. Cell Biol. 2013;203(2):171–173. doi: 10.1083/jcb.201309130. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

24. Tabares L., Betz B. Multiple functions of the vesicular proton pump in nerve terminals. Neuron. 2010;68(6):1020–1022. doi: 10.1016/j.neuron.2010.12.012. [PubMed] [CrossRef] [Google Scholar]

25. Cheng F.C., Ho Y.F., Hung L.C., Chen C.F., Tsai T.H. Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and high-performance liquid chromatography. J. Chromatogr. A. 2002;949(1-2):35–42. doi: 10.1016/S0021-9673(01)01225-0. [PubMed] [CrossRef] [Google Scholar]

26. Rojo L.E., Alzate-Morales J., Saavedra I.N., Davies P., Maccioni R.B. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer’s disease. J. Alzheimers Dis. 2010;19(2):573–589. doi: 10.3233/JAD-2010-1262. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

27. Liang J.F., Chen Y.T., Fuh J.L., Li S.Y., Chen T.J., Tang C.H., Wang S.J. Proton pump inhibitor-related headaches: a nationwide population-based case-crossover study in Taiwan. Cephalalgia. 2015;35(3):203–210. doi: 10.1177/0333102414535114. [PubMed] [CrossRef] [Google Scholar]

28. Martin R.M., Dunn N.R., Freemantle S., Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br. J. Clin. Pharmacol. 2000;50(4):366–372. doi: 10.1046/j.1365-2125.2000.00262.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

29. Chimirri S., Aiello R., Mazzitello C., Mumoli L., Palleria C., Altomonte M., Citraro R., De Sarro G. Vertigo/dizziness as a Drugs’ adverse reaction. J. Pharmacol. Pharmacother. 2013;4(Suppl. 1):S104–S109. doi: 10.4103/0976-500X.120969. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

30. Hanneken A.M., Babai N., Thoreson W.B. Oral proton pump inhibitors disrupt horizontal cell-cone feedback and enhance visual hallucinations in macular degeneration patients. Invest. Ophthalmol. Vis. Sci. 2013;54(2):1485–1489. doi: 10.1167/iovs.12-11091. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

31. Heckmann J.G., Birklein F., Neundörfer B. Omeprazole-induced delirium. J. Neurol. 2000;247(1):56–57. doi: 10.1007/s004150050011. [PubMed] [CrossRef] [Google Scholar]

32. Yibirin M., De Oliveira D., Valera R., Plitt A.E., Lutgen S. Adverse effects associated with proton pump inhibitor use. Cureus. 2021;13(1):e12759. [PMC free article] [PubMed] [Google Scholar]

33. Cundy T., Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin. Endocrinol. (Oxf.) 2008;69(2):338–341. doi: 10.1111/j.1365-2265.2008.03194.x. [PubMed] [CrossRef] [Google Scholar]

34. Gulmez S.E., Holm A., Frederiksen H., Jensen T.G., Pedersen C., Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch. Intern. Med. 2007;167(9):950–955. doi: 10.1001/archinte.167.9.950. [PubMed] [CrossRef] [Google Scholar]

35. Howell M.D., Novack V., Grgurich P., Soulliard D., Novack L., Pencina M., Talmor D. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med. 2010;170(9):784–790. doi: 10.1001/archinternmed.2010.89. [PubMed] [CrossRef] [Google Scholar]

36. Khalili H., Huang E.S., Jacobson B.C., Camargo C.A., Jr, Feskanich D., Chan A.T. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012;344:e372. doi: 10.1136/bmj.e372. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

37. Perry I.E., Sonu I., Scarpignato C., Akiyama J., Hongo M., Vega K.J. Potential proton pump inhibitor-related adverse effects. Ann. N. Y. Acad. Sci. 2020;1481(1):43–58. doi: 10.1111/nyas.14428. [PubMed] [CrossRef] [Google Scholar]

38. Yu L.Y., Sun L.N., Zhang X.H., Li Y.Q., Yu L., Yuan Z.Q., Meng L., Zhang H.W., Wang Y.Q. A review of the novel application and potential adverse effects of proton pump inhibitors. Adv. Ther. 2017;34(5):1070–1086. doi: 10.1007/s12325-017-0532-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

39. Almario C.V., Chey W.D., Spiegel B.M.R. Increased risk of COVID-19 among users of proton pump inhibitors. Am. J. Gastroenterol. 2020;115(10):1707–1715. doi: 10.14309/ajg.0000000000000798. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

40. Lee S.W., Ha E.K., Yeniova A.O., Moon S.Y., Kim S.Y., Koh H.Y., Yang J.M., Jeong S.J., Moon S.J., Cho J.Y., Yoo I.K., Yon D.K. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2021;70(1):76–84. doi: 10.1136/gutjnl-2020-322248. [PubMed] [CrossRef] [Google Scholar]

41. Price E., Treacher D.F. Reduced gastric acidity, proton pump inhibitors and increased severity of COVID-19 infections. Crit. Care. 2021;25(1):73. doi: 10.1186/s13054-021-03497-6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

42. Prince M.W.A., Guerchet M., Claire Ali G., Wu Y-T., Prina M. Alzheimer report 2015: the global impact of dementia: An analysis of prevalence, incidence, cost and trends, Alzheimer’s disease international. ADI; 2015. Available from: https://www.alzint.org/resource/world-alzheimer-report-2015/ [Google Scholar]

43. World Health Organization, Dementia: a Public Health Priority. Geneva: World Health Organization; 2012. WHO. Available from: https://apps.who.int/iris/handle/10665/75263. [Google Scholar]

44. Querfurth H.W., LaFerla F.M. Alzheimer’s disease. N. Engl. J. Med. 2010;362(4):329–344. doi: 10.1056/NEJMra0909142. [PubMed] [CrossRef] [Google Scholar]

45. Matyas N., Auer S., Gisinger C., Kil M., Keser Aschenberger F., Klerings I., Gartlehner G. Continuing education for the prevention of mild cognitive impairment and Alzheimer’s-type dementia: a systematic review protocol. Syst. Rev. 2017;6(1):157. doi: 10.1186/s13643-017-0553-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

46. doi: 10.1002/alz.12362. Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population estimate of people with clinical AD and mild cognitive impairment in the United States (2020-2060). Alzheimers Dement. 2021 May 27. (Online ahead of print). [PMC free article] [PubMed] [CrossRef] [Google Scholar]

47. Report As A. 2021 Alzheimer’s disease facts and figures. Alzheimers Dement. 2021;17(3):327–406. doi: 10.1002/alz.12328. [PubMed] [CrossRef] [Google Scholar]

48. Rajan K.B., Weuve J., Barnes L.L., Wilson R.S., Evans D.A. Prevalence and incidence of clinically diagnosed Alzheimer’s disease dementia from 1994 to 2012 in a population study. Alzheimers Dement. 2019;15(1):1–7. doi: 10.1016/j.jalz.2018.07.216. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

49. Tom S.E., Hubbard R.A., Crane P.K., Haneuse S.J., Bowen J., McCormick W.C., McCurry S., Larson E.B. Characterization of dementia and Alzheimer’s disease in an older population: updated incidence and life expectancy with and without dementia. Am. J. Public Health. 2015;105(2):408–413. doi: 10.2105/AJPH.2014.301935. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

50. Hebert L.E., Beckett L.A., Scherr P.A., Evans D.A. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis. Assoc. Disord. 2001;15(4):169–173. doi: 10.1097/00002093-200110000-00002. [PubMed] [CrossRef] [Google Scholar]

51. Hebert L.E., Bienias J.L., Aggarwal N.T., Wilson R.S., Bennett D.A., Shah R.C., Evans D.A. Change in risk of Alzheimer disease over time. Neurology. 2010;75(9):786–791. doi: 10.1212/WNL.0b013e3181f0754f. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

52. Nelson P.T., Head E., Schmitt F.A., Davis P.R., Neltner J.H., Jicha G.A., Abner E.L., Smith C.D., Van Eldik L.J., Kryscio R.J., Scheff S.W. Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies. Acta Neuropathol. 2011;121(5):571–587. doi: 10.1007/s00401-011-0826-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

53. Chêne G., Beiser A., Au R., Preis S.R., Wolf P.A., Dufouil C., Seshadri S. Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. Alzheimers Dement. 2015;11(3):310–320. doi: 10.1016/j.jalz.2013.10.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

54. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J., et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology. 1993;43(8):1467–1472. doi: 10.1212/WNL.43.8.1467. [PubMed] [CrossRef] [Google Scholar]

55. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA. 1997;278(16):1349–1356. doi: 10.1001/jama.1997.03550160069041. [PubMed] [CrossRef] [Google Scholar]

56. Rajan K.B., Barnes L.L., Wilson R.S., McAninch E.A., Weuve J., Sighoko D., Evans D.A. Racial differences in the association between apolipoprotein E risk alleles and overall and total cardiovascular mortality over 18 years. J. Am. Geriatr. Soc. 2017;65(11):2425–2430. doi: 10.1111/jgs.15059. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

57. Evans D.A., Bennett D.A., Wilson R.S., Bienias J.L., Morris M.C., Scherr P.A., Hebert L.E., Aggarwal N., Beckett L.A., Joglekar R., Berry-Kravis E., Schneider J. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch. Neurol. 2003;60(2):185–189. doi: 10.1001/archneur.60.2.185. [PubMed] [CrossRef] [Google Scholar]

58. Tang M.X., Stern Y., Marder K., Bell K., Gurland B., Lantigua R., Andrews H., Feng L., Tycko B., Mayeux R. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998;279(10):751–755. doi: 10.1001/jama.279.10.751. [PubMed] [CrossRef] [Google Scholar]

59. Loy C.T., Schofield P.R., Turner A.M., Kwok J.B. Genetics of dementia. Lancet. 2014;383(9919):828–840. doi: 10.1016/S0140-6736(13)60630-3. [PubMed] [CrossRef] [Google Scholar]

60. Holtzman D.M., Herz J., Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012;2(3):a006312. doi: 10.1101/cshperspect.a006312. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

61. Michaelson D.M. APOE ε4: the most prevalent yet understudied risk factor for Alzheimer’s disease. Alzheimers Dement. 2014;10(6):861–868. doi: 10.1016/j.jalz.2014.06.015. [PubMed] [CrossRef] [Google Scholar]

62. Jansen W.J., Ossenkoppele R., Knol D.L., Tijms B.M., Scheltens P., Verhey F.R., Visser P.J., Aalten P., Aarsland D., Alcolea D., Alexander M., Almdahl I.S., Arnold S.E., Baldeiras I., Barthel H., van Berckel B.N., Bibeau K., Blennow K., Brooks D.J., van Buchem M.A., Camus V., Cavedo E., Chen K., Chetelat G., Cohen A.D., Drzezga A., Engelborghs S., Fagan A.M., Fladby T., Fleisher A.S., van der Flier W.M., Ford L., Förster S., Fortea J., Foskett N., Frederiksen K.S., Freund-Levi Y., Frisoni G.B., Froelich L., Gabryelewicz T., Gill K.D., Gkatzima O., Gómez-Tortosa E., Gordon M.F., Grimmer T., Hampel H., Hausner L., Hellwig S., Herukka S.K., Hildebrandt H., Ishihara L., Ivanoiu A., Jagust W.J., Johannsen P., Kandimalla R., Kapaki E., Klimkowicz-Mrowiec A., Klunk W.E., Köhler S., Koglin N., Kornhuber J., Kramberger M.G., Van Laere K., Landau S.M., Lee D.Y., de Leon M., Lisetti V., Lleó A., Madsen K., Maier W., Marcusson J., Mattsson N., de Mendonça A., Meulenbroek O., Meyer P.T., Mintun M.A., Mok V., Molinuevo J.L., Møllergård H.M., Morris J.C., Mroczko B., Van der Mussele S., Na D.L., Newberg A., Nordberg A., Nordlund A., Novak G.P., Paraskevas G.P., Parnetti L., Perera G., Peters O., Popp J., Prabhakar S., Rabinovici G.D., Ramakers I.H., Rami L., Resende de Oliveira C., Rinne J.O., Rodrigue K.M., Rodríguez-Rodríguez E., Roe C.M., Rot U., Rowe C.C., Rüther E., Sabri O., Sanchez-Juan P., Santana I., Sarazin M., Schröder J., Schütte C., Seo S.W., Soetewey F., Soininen H., Spiru L., Struyfs H., Teunissen C.E., Tsolaki M., Vandenberghe R., Verbeek M.M., Villemagne V.L., Vos S.J., van Waalwijk van Doorn L.J., Waldemar G., Wallin A., Wallin Å.K., Wiltfang J., Wolk D.A., Zboch M., Zetterberg H. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924–1938. doi: 10.1001/jama.2015.4668. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

63. Spinney L. Alzheimer’s disease: The forgetting gene. Nature. 2014;510(7503):26–28. doi: 10.1038/510026a. [PubMed] [CrossRef] [Google Scholar]

64. Mayeux R., Saunders A.M., Shea S., Mirra S., Evans D., Roses A.D., Hyman B.T., Crain B., Tang M.X., Phelps C.H. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. N. Engl. J. Med. 1998;338(8):506–511. doi: 10.1056/NEJM199802193380804. [PubMed] [CrossRef] [Google Scholar]

65. Ward A., Crean S., Mercaldi C.J., Collins J.M., Boyd D., Cook M.N., Arrighi H.M. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer’s disease: a systematic review and meta-analysis. Neuroepidemiology. 2012;38(1):1–17. doi: 10.1159/000334607. [PubMed] [CrossRef] [Google Scholar]

66. Dekhtyar S., Marseglia A., Xu W., Darin-Mattsson A., Wang H.X., Fratiglioni L. Genetic risk of dementia mitigated by cognitive reserve: A cohort study. Ann. Neurol. 2019;86(1):68–78. doi: 10.1002/ana.25501. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

67. Bekris L.M., Yu C.E., Bird T.D., Tsuang D.W. Genetics of Alzheimer disease. J. Geriatr. Psychiatry Neurol. 2010;23(4):213–227. doi: 10.1177/0891988710383571. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

68. Goldman J.S., Hahn S.E., Catania J.W., LaRusse-Eckert S., Butson M.B., Rumbaugh M., Strecker M.N., Roberts J.S., Burke W., Mayeux R., Bird T. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet. Med. 2011;13(6):597–605. doi: 10.1097/GIM.0b013e31821d69b8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

69. Snyder H.M., Bain L.J., Brickman A.M., Carrillo M.C., Esbensen A.J., Espinosa J.M., Fernandez F., Fortea J., Hartley S.L., Head E., Hendrix J., Kishnani P.S., Lai F., Lao P., Lemere C., Mobley W., Mufson E.J., Potter H., Zaman S.H., Granholm A.C., Rosas H.D., Strydom A., Whitten M.S., Rafii M.S. Further understanding the connection between Alzheimer’s disease and Down syndrome. Alzheimers Dement. 2020;16(7):1065–1077. doi: 10.1002/alz.12112. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

70. Green R.C., Cupples L.A., Go R., Benke K.S., Edeki T., Griffith P.A., Williams M., Hipps Y., Graff-Radford N., Bachman D., Farrer L.A. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA. 2002;287(3):329–336. doi: 10.1001/jama.287.3.329. [PubMed] [CrossRef] [Google Scholar]

71. Lautenschlager N.T., Cupples L.A., Rao V.S., Auerbach S.A., Becker R., Burke J., Chui H., Duara R., Foley E.J., Glatt S.L., Green R.C., Jones R., Karlinsky H., Kukull W.A., Kurz A., Larson E.B., Martelli K., Sadovnick A.D., Volicer L., Waring S.C., Growdon J.H., Farrer L.A. Risk of dementia among relatives of Alzheimer’s disease patients in the MIRAGE study: What is in store for the oldest old? Neurology. 1996;46(3):641–650. doi: 10.1212/WNL.46.3.641. [PubMed] [CrossRef] [Google Scholar]

72. Vermunt L., Sikkes S.A.M., van den Hout A., Handels R., Bos I., van der Flier W.M., Kern S., Ousset P.J., Maruff P., Skoog I., Verhey F.R.J., Freund-Levi Y., Tsolaki M., Wallin Å.K., Olde Rikkert M., Soininen H., Spiru L., Zetterberg H., Blennow K., Scheltens P., Muniz-Terrera G., Visser P.J. Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019;15(7):888–898. doi: 10.1016/j.jalz.2019.04.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

73. Samieri C., Perier M.C., Gaye B., Proust-Lima C., Helmer C., Dartigues J.F., Berr C., Tzourio C., Empana J.P. Association of cardiovascular health level in older age with cognitive decline and incident dementia. JAMA. 2018;320(7):657–664. doi: 10.1001/jama.2018.11499. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

74. Anstey K.J., von Sanden C., Salim A., O’Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am. J. Epidemiol. 2007;166(4):367–378. doi: 10.1093/aje/kwm116. [PubMed] [CrossRef] [Google Scholar]

75. Rusanen M., Kivipelto M., Quesenberry C.P., Jr, Zhou J., Whitmer R.A. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch. Intern. Med. 2011;171(4):333–339. doi: 10.1001/archinternmed.2010.393. [PubMed] [CrossRef] [Google Scholar]

76. Beydoun M.A., Beydoun H.A., Gamaldo A.A., Teel A., Zonderman A.B., Wang Y. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health. 2014;14:643. doi: 10.1186/1471-2458-14-643. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

77. Ohara T., Ninomiya T., Hata J., Ozawa M., Yoshida D., Mukai N., Nagata M., Iwaki T., Kitazono T., Kanba S., Kiyohara Y. Midlife and late-life smoking and risk of dementia in the community: The hisayama study. J. Am. Geriatr. Soc. 2015;63(11):2332–2339. doi: 10.1111/jgs.13794. [PubMed] [CrossRef] [Google Scholar]

78. Choi D., Choi S., Park S.M. Effect of smoking cessation on the risk of dementia: A longitudinal study. Ann. Clin. Transl. Neurol. 2018;5(10):1192–1199. doi: 10.1002/acn3.633. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

79. Wu W., Brickman A.M., Luchsinger J., Ferrazzano P., Pichiule P., Yoshita M., Brown T., DeCarli C., Barnes C.A., Mayeux R., Vannucci S.J., Small S.A. The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Ann. Neurol. 2008;64(6):698–706. doi: 10.1002/ana.21557. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

80. Gudala K., Bansal D., Schifano F., Bhansali A. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J. Diabetes Investig. 2013;4(6):640–650. doi: 10.1111/jdi.12087. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

81. Vagelatos N.T., Eslick G.D. Type 2 diabetes as a risk factor for Alzheimer’s disease: the confounders, interactions, and neuropathology associated with this relationship. Epidemiol. Rev. 2013;35:152–160. doi: 10.1093/epirev/mxs012. [PubMed] [CrossRef] [Google Scholar]

82. Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 2011;7(3):137–152. doi: 10.1038/nrneurol.2011.2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

83. Rönnemaa E., Zethelius B., Lannfelt L., Kilander L. Vascular risk factors and dementia: 40-year follow-up of a population-based cohort. Dement. Geriatr. Cogn. Disord. 2011;31(6):460–466. doi: 10.1159/000330020. [PubMed] [CrossRef] [Google Scholar]

84. Kivimäki M., Luukkonen R., Batty G.D., Ferrie J.E., Pentti J., Nyberg S.T., Shipley M.J., Alfredsson L., Fransson E.I., Goldberg M., Knutsson A., Koskenvuo M., Kuosma E., Nordin M., Suominen S.B., Theorell T., Vuoksimaa E., Westerholm P., Westerlund H., Zins M., Kivipelto M., Vahtera J., Kaprio J., Singh-Manoux A., Jokela M. Body mass index and risk of dementia: Analysis of individual-level data from 1.3 million individuals. Alzheimers Dement. 2018;14(5):601–609. doi: 10.1016/j.jalz.2017.09.016. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

85. Loef M., Walach H. Midlife obesity and dementia: meta-analysis and adjusted forecast of dementia prevalence in the United States and China. Obesity (Silver Spring) 2013;21(1):E51–E55. doi: 10.1002/oby.20037. [PubMed] [CrossRef] [Google Scholar]

86. Anstey K.J., Cherbuin N., Budge M., Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes. Rev. 2011;12(5):e426–e437. doi: 10.1111/j.1467-789X.2010.00825.x. [PubMed] [CrossRef] [Google Scholar]

87. Gottesman R.F., Albert M.S., Alonso A., Coker L.H., Coresh J., Davis S.M., Deal J.A., McKhann G.M., Mosley T.H., Sharrett A.R., Schneider A.L.C., Windham B.G., Wruck L.M., Knopman D.S. Associations between midlife vascular risk factors and 25-year incident dementia in the atherosclerosis risk in communities (ARIC) cohort. JAMA Neurol. 2017;74(10):1246–1254. doi: 10.1001/jamaneurol.2017.1658. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

88. Abell J.G., Kivimäki M., Dugravot A., Tabak A.G., Fayosse A., Shipley M., Sabia S., Singh-Manoux A. Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. Eur. Heart J. 2018;39(33):3119–3125. doi: 10.1093/eurheartj/ehy288. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

89. Ninomiya T., Ohara T., Hirakawa Y., Yoshida D., Doi Y., Hata J., Kanba S., Iwaki T., Kiyohara Y. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. Hypertension. 2011;58(1):22–28. doi: 10.1161/HYPERTENSIONAHA.110.163055. [PubMed] [CrossRef] [Google Scholar]

90. Debette S., Seshadri S., Beiser A., Au R., Himali J.J., Palumbo C., Wolf P.A., DeCarli C. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology. 2011;77(5):461–468. doi: 10.1212/WNL.0b013e318227b227. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

91. Livingston G., Sommerlad A., Orgeta V., Costafreda S.G., Huntley J., Ames D., Ballard C., Banerjee S., Burns A., Cohen-Mansfield J., Cooper C., Fox N., Gitlin L.N., Howard R., Kales H.C., Larson E.B., Ritchie K., Rockwood K., Sampson E.L., Samus Q., Schneider L.S., Selbæk G., Teri L., Mukadam N. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–2734. doi: 10.1016/S0140-6736(17)31363-6. [PubMed] [CrossRef] [Google Scholar]

92. Solomon A., Kivipelto M., Wolozin B., Zhou J., Whitmer R.A. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement. Geriatr. Cogn. Disord. 2009;28(1):75–80. doi: 10.1159/000231980. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

93. Meng X.F., Yu J.T., Wang H.F., Tan M.S., Wang C., Tan C.C., Tan L. Midlife vascular risk factors and the risk of Alzheimer’s disease: a systematic review and meta-analysis. J. Alzheimers Dis. 2014;42(4):1295–1310. doi: 10.3233/JAD-140954. [PubMed] [CrossRef] [Google Scholar]

94. Aisen P.S., Cummings J., Jack C.R., Jr, Morris J.C., Sperling R., Frölich L., Jones R.W., Dowsett S.A., Matthews B.R., Raskin J., Scheltens P., Dubois B. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res. Ther. 2017;9(1):60. doi: 10.1186/s13195-017-0283-5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

95. Rehm J., Hasan O.S.M., Black S.E., Shield K.D., Schwarzinger M. Alcohol use and dementia: a systematic scoping review. Alzheimers Res. Ther. 2019;11(1):1. doi: 10.1186/s13195-018-0453-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

96. Cherbuin N., Kim S., Anstey K.J. Dementia risk estimates associated with measures of depression: a systematic review and meta-analysis. BMJ Open. 2015;5(12):e008853. doi: 10.1136/bmjopen-2015-008853. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

97. Thomson R.S., Auduong P., Miller A.T., Gurgel R.K. Hearing loss as a risk factor for dementia: a systematic review. Laryngoscope Investig. Otolaryngol. 2017;2(2):69–79. doi: 10.1002/lio2.65. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

98. Fitzpatrick A.L., Kuller L.H., Lopez O.L., Diehr P., O’Meara E.S., Longstreth W.T., Jr, Luchsinger J.A. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch. Neurol. 2009;66(3):336–342. doi: 10.1001/archneurol.2008.582. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

99. Corrada M.M., Hayden K.M., Paganini-Hill A., Bullain S.S., DeMoss J., Aguirre C., Brookmeyer R., Kawas C.H. Age of onset of hypertension and risk of dementia in the oldest-old: The 90+ Study. Alzheimers Dement. 2017;13(2):103–110. doi: 10.1016/j.jalz.2016.09.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

100. Barnes D.E., Byers A.L., Gardner R.C., Seal K.H., Boscardin W.J., Yaffe K. Association of mild traumatic brain injury with and without loss of consciousness with dementia in US military veterans. JAMA Neurol. 2018;75(9):1055–1061. doi: 10.1001/jamaneurol.2018.0815. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

101. Asken B.M., Sullan M.J., DeKosky S.T., Jaffee M.S., Bauer R.M. Research gaps and controversies in chronic traumatic encephalopathy: A review. JAMA Neurol. 2017;74(10):1255–1262. doi: 10.1001/jamaneurol.2017.2396. [PubMed] [CrossRef] [Google Scholar]

102. Bernard S.M., McGeehin M.A. Prevalence of blood lead levels >or= 5 micro g/dL among US children 1 to 5 years of age and socioeconomic and demographic factors associated with blood of lead levels 5 to 10 micro g/dL, Third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics. 2003;112(6 Pt 1):1308–1313. doi: 10.1542/peds.112.6.1308. [PubMed] [CrossRef] [Google Scholar]

103. Griffith M., Tajik M., Wing S. Patterns of agricultural pesticide use in relation to socioeconomic characteristics of the population in the rural U.S. South. Int. J. Health Serv. 2007;37(2):259–277. doi: 10.2190/R410-7263-4811-4415. [PubMed] [CrossRef] [Google Scholar]

104. doi: 10.1159/000515162. Lin FC, Chen CY, Lin CW, Wu MT, Chen HY, Huang P. Air pollution is associated with cognitive deterioration of Alzheimer’s disease. Gerontology 2021; 1-9. [PubMed] [CrossRef] [Google Scholar]

105. Younan D., Petkus A.J., Widaman K.F., Wang X., Casanova R., Espeland M.A., Gatz M., Henderson V.W., Manson J.E., Rapp S.R., Sachs B.C., Serre M.L., Gaussoin S.A., Barnard R., Saldana S., Vizuete W., Beavers D.P., Salinas J.A., Chui H.C., Resnick S.M., Shumaker S.A., Chen J.C. Particulate matter and episodic memory decline mediated by early neuroanatomic biomarkers of Alzheimer’s disease. Brain. 2020;143(1):289–302. doi: 10.1093/brain/awz348. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

106. Peters R., Ee N., Peters J., Booth A., Mudway I., Anstey K.J. Air pollution and dementia: A systematic review. J. Alzheimers Dis. 2019;70(s1):S145–S163. doi: 10.3233/JAD-180631. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

107. Kulick E.R., Wellenius G.A., Boehme A.K., Joyce N.R., Schupf N., Kaufman J.D., Mayeux R., Sacco R.L., Manly J.J., Elkind M.S.V. Long-term exposure to air pollution and trajectories of cognitive decline among older adults. Neurology. 2020;94(17):e1782–e1792. doi: 10.1212/WNL.0000000000009314. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

108. Fitzpatrick A.L., Kuller L.H., Ives D.G., Lopez O.L., Jagust W., Breitner J.C., Jones B., Lyketsos C., Dulberg C. Incidence and prevalence of dementia in the cardiovascular health study. J. Am. Geriatr. Soc. 2004;52(2):195–204. doi: 10.1111/j.1532-5415.2004.52058.x. [PubMed] [CrossRef] [Google Scholar]

109. Kukull W.A., Higdon R., Bowen J.D., McCormick W.C., Teri L., Schellenberg G.D., van Belle G., Jolley L., Larson E.B. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch. Neurol. 2002;59(11):1737–1746. doi: 10.1001/archneur.59.11.1737. [PubMed] [CrossRef] [Google Scholar]

110. Sando S.B., Melquist S., Cannon A., Hutton M., Sletvold O., Saltvedt I., White L.R., Lydersen S., Aasly J. Risk-reducing effect of education in Alzheimer’s disease. Int. J. Geriatr. Psychiatry. 2008;23(11):1156–1162. doi: 10.1002/gps.2043. [PubMed] [CrossRef] [Google Scholar]

111. Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol. 2012;11(11):1006–1012. doi: 10.1016/S1474-4422(12)70191-6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

112. Hendrie H.C., Smith-Gamble V., Lane K.A., Purnell C., Clark D.O., Gao S. The association of early life factors and declining incidence rates of dementia in an elderly population of African Americans. J. Gerontol. B Psychol. Sci. Soc. Sci. 2018;73(Suppl. 1):S82–S89. doi: 10.1093/geronb/gbx143. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

113. Stern Y., Arenaza-Urquijo E.M., Bartrés-Faz D., Belleville S., Cantilon M., Chetelat G., Ewers M., Franzmeier N., Kempermann G., Kremen W.S., Okonkwo O., Scarmeas N., Soldan A., Udeh-Momoh C., Valenzuela M., Vemuri P., Vuoksimaa E. Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance. Alzheimers Dement. 2020;16(9):1305–1311. doi: 10.1016/j.jalz.2018.07.219. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

114. Menke A., Casagrande S., Geiss L., Cowie C.C. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA. 2015;314(10):1021–1029. doi: 10.1001/jama.2015.10029. [PubMed] [CrossRef] [Google Scholar]

115. Sims M., Diez Roux A.V., Boykin S., Sarpong D., Gebreab S.Y., Wyatt S.B., Hickson D., Payton M., Ekunwe L., Taylor H.A. The socioeconomic gradient of diabetes prevalence, awareness, treatment, and control among African Americans in the jackson heart study. Ann. Epidemiol. 2011;21(12):892–898. doi: 10.1016/j.annepidem.2011.05.006. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

116. Lee T.C., Glynn R.J., Peña J.M., Paynter N.P., Conen D., Ridker P.M., Pradhan A.D., Buring J.E., Albert M.A. Socioeconomic status and incident type 2 diabetes mellitus: data from the Women’s Health Study. PLoS One. 2011;6(12):e27670. doi: 10.1371/journal.pone.0027670. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

117. Gillespie C.D., Hurvitz K.A. Centers for Disease Control and Prevention (CDC) Prevalence of hypertension and controlled hypertension - United States, 2007-2010. MMWR Suppl. 2013;62(3):144–148. [PubMed] [Google Scholar]

118. Durazzo T.C., Mattsson N., Weiner M.W. Alzheimer’s disease neuroimaging initiative. Smoking and increased Alzheimer’s disease risk: A review of potential mechanisms. Alzheimers Dement. 2014;10(3):S122–S145. doi: 10.1016/j.jalz.2014.04.009. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

119. Haenisch B., von Holt K., Wiese B., Prokein J., Lange C., Ernst A., Brettschneider C., König H.H., Werle J., Weyerer S., Luppa M., Riedel-Heller S.G., Fuchs A., Pentzek M., Weeg D., Bickel H., Broich K., Jessen F., Maier W., Scherer M. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur. Arch. Psychiatry Clin. Neurosci. 2015;265(5):419–428. doi: 10.1007/s00406-014-0554-0. [PubMed] [CrossRef] [Google Scholar]

120. Kuller L.H. Do proton pump inhibitors increase the risk of dementia? JAMA Neurol. 2016;73(4):379–381. doi: 10.1001/jamaneurol.2015.4931. [PubMed] [CrossRef] [Google Scholar]

121. Wise J. Proton pump inhibitors may be linked to dementia risk. BMJ. 2016;352:i972. doi: 10.1136/bmj.i972. [PubMed] [CrossRef] [Google Scholar]

122. Zuercher S. Développement des démences: les inhibiteurs de la pompe à protons impliqués? Rev Med Suisse 2016; 12(513): 716. [PubMed] [Google Scholar]

123. Waldum H.L. Proton pump inhibitors and gastric cancer. Tidsskr. Nor. Laegeforen. 2016;136(1):13–14. doi: 10.4045/tidsskr.15.1032. [PubMed] [CrossRef] [Google Scholar]

124. Venci J.V., Eisenberg K.W. Proton pump inhibitors and dementia incidence. JAMA Neurol. 2016;73(8):1026. doi: 10.1001/jamaneurol.2016.1500. [PubMed] [CrossRef] [Google Scholar]

125. Freeman W.D. Proton pump inhibitors and dementia incidence. JAMA Neurol. 2016;73(8):1026–1027. doi: 10.1001/jamaneurol.2016.1503. [PubMed] [CrossRef] [Google Scholar]

126. Sharma K., Minagar A., Sun H. Proton pump inhibitors and dementia incidence. JAMA Neurol. 2016;73(8):1027. doi: 10.1001/jamaneurol.2016.1959. [PubMed] [CrossRef] [Google Scholar]

127. Nguyen L., Hur C. Proton pump inhibitors and dementia incidence. JAMA Neurol. 2016;73(8):1027–1028. doi: 10.1001/jamaneurol.2016.1962. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

128. Keller D.L. Proton pump inhibitors and dementia incidence. JAMA Neurol. 2016;73(8):1025. doi: 10.1001/jamaneurol.2016.1488. [PubMed] [CrossRef] [Google Scholar]

129. Kawada T. Proton pump inhibitors and dementia incidence. JAMA Neurol. 2016;73(8):1025–1026. doi: 10.1001/jamaneurol.2016.1491. [PubMed] [CrossRef] [Google Scholar]

130. Huat T.J., Camats-Perna J., Newcombe E.A., Valmas N., Kitazawa M., Medeiros R. Metal toxicity links to Alzheimer’s disease and neuroinflammation. J. Mol. Biol. 2019;431(9):1843–1868. doi: 10.1016/j.jmb.2019.01.018. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

131. Wang Z., Wei X., Yang J., Suo J., Chen J., Liu X., Zhao X. Chronic exposure to aluminum and risk of Alzheimer’s disease: A meta-analysis. Neurosci. Lett. 2016;610:200–206. doi: 10.1016/j.neulet.2015.11.014. [PubMed] [CrossRef] [Google Scholar]

132. Wijarnpreecha K., Thongprayoon C., Panjawatanan P., Ungprasert P. Proton pump inhibitors and risk of dementia. Ann. Transl. Med. 2016;4(12):240. doi: 10.21037/atm.2016.06.14. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

133. Badiola N., Alcalde V., Pujol A., Münter L.M., Multhaup G., Lleó A., Coma M., Soler-López M., Aloy P. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013;8(3):e58837. doi: 10.1371/journal.pone.0058837. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

134. Kumar R., Kumar A., Nordberg A., Långström B., Darreh-Shori T. Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme-A plausible missing link for their association with incidence of dementia. Alzheimers Dement. 2020;16(7):1031–1042. doi: 10.1002/alz.12113. [PubMed] [CrossRef] [Google Scholar]

135. Ortiz-Guerrero G., Amador-Muñoz D., Calderón-Ospina C.A., López-Fuentes D., Nava Mesa M.O. Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences. Neural Plast. 2018;2018:5257285. doi: 10.1155/2018/5257285. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

136. Booker A., Jacob L.E., Rapp M., Bohlken J., Kostev K. Risk factors for dementia diagnosis in German primary care practices. Int. Psychogeriatr. 2016;28(7):1059–1065. doi: 10.1017/S1041610215002082. [PubMed] [CrossRef] [Google Scholar]

137. Taipale H., Tolppanen A.M., Tiihonen M., Tanskanen A., Tiihonen J., Hartikainen S. No association between proton pump inhibitor use and risk of Alzheimer’s disease. Am. J. Gastroenterol. 2017;112(12):1802–1808. doi: 10.1038/ajg.2017.196. [PubMed] [CrossRef] [Google Scholar]

138. Lochhead P., Hagan K., Joshi A.D., Khalili H., Nguyen L.H., Grodstein F., Chan A.T. Association between proton pump inhibitor use and cognitive function in women. Gastroenterology. 2017;153(4):971–979.e4. doi: 10.1053/j.gastro.2017.06.061. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

139. Gray S.L., Walker R.L., Dublin S., Yu O., Aiello Bowles E.J., Anderson M.L., Crane P.K., Larson E.B. Proton pump inhibitor use and dementia risk: Prospective population-based study. J. Am. Geriatr. Soc. 2018;66(2):247–253. doi: 10.1111/jgs.15073. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

140. Moayyedi P., Lewis M.A. Proton pump inhibitors and dementia: Deciphering the data. Am. J. Gastroenterol. 2017;112(12):1809–1811. doi: 10.1038/ajg.2017.415. [PubMed] [CrossRef] [Google Scholar]

141. Batchelor R., Gilmartin J.F., Kemp W., Hopper I., Liew D. Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review. J. Gastroenterol. Hepatol. 2017;32(8):1426–1435. doi: 10.1111/jgh.13750. [PubMed] [CrossRef] [Google Scholar]

142. Imfeld P., Bodmer M., Jick S.S., Meier C.R. Proton pump inhibitor use and risk of developing Alzheimer’s disease or vascular dementia: A case-control analysis. Drug Saf. 2018;41(12):1387–1396. doi: 10.1007/s40264-018-0704-9. [PubMed] [CrossRef] [Google Scholar]

143. Hwang I.C., Chang J., Park S.M. A nationwide population-based cohort study of dementia risk among acid suppressant users. Am. J. Geriatr. Psychiatry. 2018;26(11):1175–1183. doi: 10.1016/j.jagp.2018.06.002. [PubMed] [CrossRef] [Google Scholar]

144. Cooksey R., Kennedy J., Dennis M.S., Escott-Price V., Lyons R.A., Seaborne M., Brophy S. Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. PLoS One. 2020;15(9):e0237676. doi: 10.1371/journal.pone.0237676. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

145. Torres-Bondia F., Dakterzada F., Galván L., Buti M., Besanson G., Gill E., Buil R., de Batlle J., Piñol-Ripoll G. Proton pump inhibitors and the risk of Alzheimer’s disease and non-Alzheimer’s dementias. Sci. Rep. 2020;10(1):21046. doi: 10.1038/s41598-020-78199-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

146. doi: 10.1080/23279095.2021.1883019. Collin BG, Raju D, Altman J, Katsikas S. The effects of proton pump inhibitors on neuropsychological functioning. Appl Neuropsychol Adult 2021; 1-10. (Online ahead of print). [PubMed] [CrossRef] [Google Scholar]

147. Ahn N., Frenzel S., Wittfeld K., Bülow R., Völzke H., Lerch M.M., Chenot J.F., Schminke U., Nolde M., Amann U., Meisinger C., Linseisen J., Baumeister S.E., Grabe H.J., Rückert-Eheberg I.M. Lack of association between proton pump inhibitor use and brain aging: a cross-sectional study. Eur. J. Clin. Pharmacol. 2021;77(7):1039–1048. doi: 10.1007/s00228-020-03068-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

148. Li M., Luo Z., Yu S., Tang Z. Proton pump inhibitor use and risk of dementia: Systematic review and meta-analysis. Medicine (Baltimore) 2019;98(7):e14422. doi: 10.1097/MD.0000000000014422. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

149. Desai M., Nutalapati V., Srinivasan S., Fathallah J., Dasari C., Chandrasekhar V.T., Mohammad B., Kohli D., Vaezi M., Katz P.O., Sharma P. Proton pump inhibitors do not increase the risk of dementia: a systematic review and meta-analysis of prospective studies. Dis. Esophagus. 2020;33(10):doaa041. doi: 10.1093/dote/doaa041. [PubMed] [CrossRef] [Google Scholar]

150. Khan M.A., Yuan Y., Iqbal U., Kamal S., Khan M., Khan Z., Lee W.M., Howden C.W. No association linking short-term proton pump inhibitor use to dementia: Systematic review and meta-analysis of observational studies. Am. J. Gastroenterol. 2020;115(5):671–678. doi: 10.14309/ajg.0000000000000500. [PubMed] [CrossRef] [Google Scholar]

151. Song Y.Q., Li Y., Zhang S.L., Gao J., Feng S.Y. Proton pump inhibitor use does not increase dementia and Alzheimer’s disease risk: An updated meta-analysis of published studies involving 642305 patients. PLoS One. 2019;14(7):e0219213. doi: 10.1371/journal.pone.0219213. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

152. Zhang Y., Liang M., Sun C., Song E.J., Cheng C., Shi T., Min M., Sun Y. Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies. Eur. J. Clin. Pharmacol. 2020;76(2):139–147. doi: 10.1007/s00228-019-02753-7. [PubMed] [CrossRef] [Google Scholar]

153. Zhang Y., Zhan J., Bao Q., Lu J., Tan L. Possible dementia risk of proton pump inhibitors and H2 receptor blockers use in the treatment of Helicobacter pylori: A meta-analysis study. Med. Hypotheses. 2020;144:109989. doi: 10.1016/j.mehy.2020.109989. [PubMed] [CrossRef] [Google Scholar]

154. Thunell J., Chen Y., Joyce G., Barthold D., Shekelle P.G., Brinton R.D., Zissimopoulos J. Drug therapies for chronic conditions and risk of Alzheimer’s disease and related dementias: A scoping review. Alzheimers Dement. 2021;17(1):41–48. doi: 10.1002/alz.12175. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

155. Chen L.Y., Lin H.J., Wu W.T., Chen Y.C., Chen C.L., Kao J., You S.L., Chou Y.C., Sun C.A. Clinical use of acid suppressants and risk of dementia in the elderly: A pharmaco-epidemiological cohort study. Int. J. Environ. Res. Public Health. 2020;17(21):E8271. doi: 10.3390/ijerph17218271. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

156. Wu C.L., Lei W.Y., Wang J.S., Lin C.E., Chen C.L., Wen S.H. Acid suppressants use and the risk of dementia: A population-based propensity score-matched cohort study. PLoS One. 2020;15(11):e0242975. doi: 10.1371/journal.pone.0242975. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

157. Tai S.Y., Chien C.Y., Wu D.C., Lin K.D., Ho B.L., Chang Y.H., Chang Y.P. Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan. PLoS One. 2017;12(2):e0171006. doi: 10.1371/journal.pone.0171006. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

158. Herghelegui A.M., Prada G.I., Nacu R. Prolonged use of proton pump inhibitors and cognitive function in older adults. Farmacia. 2016;(64):262–267. [Google Scholar]

159. Bebarta VS, King JA, McDonough M. Proton pump inhibitor-induced rhabdomyolysis and hyponatremic delirium. Am J Emerg Med. 2008;26(4):519 e1-2. doi: 10.1016/j.ajem.2007.08.026. [PubMed] [CrossRef] [Google Scholar]

160. Delgado MG, Calleja S, Suarez L, Pascual J. Recurrent confusional episodes associated with hypomagnesaemia due to esomeprazol. BMJ Case Rep . doi: 10.1136/bcr-2013-200501. [PMC free ar